The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Zentiva
Advising Advent International on the sale of Zentiva, a leading European generics pharmaceutical company, to GTCR, a Chicago-based private equity firm with a long history of investments in the healthcare sector
Shields Health Solutions
Sole Financial Advisor to Evernorth Health Services, a subsidiary of the Cigna Group, on its announced $3.5 billion investment in Shields Health Solutions
Plena Healthcare
Advising Australian Unity, one of Australia’s largest providers of in-home care services, on its acquisition of Plena Healthcare, a national provider of mobile allied health services within residential aged care and community settings, from Zenitas Healthcare
Perrigo Company Plc Branded Dermacosmetics business
Advising Perrigo Company plc, a leading global provider of Consumer Self-Care Products, on the divestiture of its Dermacosmetics branded business in the Nordics, Netherlands and Poland to Kairos Bidco AB, an investment vehicle managed by KKR
Emergency Care Partners
Advised Emergency Care Partners (“ECP”), a leading provider of emergency department management services and its majority owner Varsity Healthcare Partners (“VHP”) on a growth recapitalization transaction, inclusive of a $100 million preferred equity investment led by MidOcean Partners (“MidOcean”)
EYSA
Advising Tikehau Capital, global mid-market fund headquartered in France, in the acquisition of EYSA, a leading provider of smart mobility solutions, focusing on both urban and interurban mobility services for municipalities, transport authorities and infrastructure owners
Pacific Smiles Group
Advised Pacific Smiles Group Limited, one of Australia’s leading and fastest growing dental service organisations, on its response to multiple private equity proposals and ultimate sale to Genesis Capital by way of off-market takeover
PRISM Vision Group
Advising PRISM Vision Group, a leading medical eye care services company, on its majority stake sale to McKesson Corporation, a diversified healthcare services and distribution leader
Ex-US rights to branded narcolepsy treatments, Provigil® (modafinil) and Nuvigil® (armodafinil)
Advised Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company, on the acquisition of the ex-US rights to Provigil® (modafinil) and Nuvigil® (armodafinil) from Teva Pharmaceuticals Industries Ltd. (“Teva”)
Centogene GmbH
Advising Charme Capital Partners, a European mid-market private equity fund, on the acquisition of Centogene GmbH, a leading provider of pharmaceutical solutions and diagnostic tests for rare diseases
Blue Owl Technology Finance Corp. II (“OTF II”)
Advised and provided a fairness opinion to the Special Committee of the Independent Directors of OTF II, a specialty finance company focused on originating and making loans to, and making debt and equity investment in, technology related companies, specifically software, based primarily in the US, on its merger with OTF
Medical Review Institute of America
Advised Medical Review Institute of America, a portfolio company of Summit Partners and a leading provider of outsourced utilization management and clinical review solutions to payors, on its strategic growth investment from Parthenon Capital
U.S. Acute Care Solutions
Advised U.S. Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on the refinancing of its senior secured notes
myHomecare Group
Advising Australian Unity on its acquisition of myHomecare Group
Slayback Pharma LLC
Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products
Central nervous system (CNS) portfolio from Sanofi
Advising Pharmanovia, a UK based global lifecycle management healthcare company, on the acquisition of a global central nervous system portfolio from Sanofi, the France based innovative global healthcare company
Clinigen Ltd’s portfolio of Established Medicines
Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners
Farmalider Group
Advising the shareholders of Grupo Farmalider, a B2B Spanish pharmaceutical company focused on contract manufacturing, innovation and development of products based on generics, on the sale of an undisclosed stake to local private equity MCH
Interest in Joint Venture with CarepathRx Health System Solutions
Advising Cigna on its investment in CarepathRx Health System Solutions, under Evernorth, Cigna’s health services subsidiary
Marley Spoon business combination with 468 SPAC II
Advising Marley Spoon SE, an ASX listed global subscription-based meal kit provider, on its business combination agreement with 468 SPAC II, simultaneous capital raising and amendment to existing debt facilities
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
Clinigen Ltd’s Lamda Laboratories
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
Gaming Services Division of Global Payments
Advising Parthenon Capital, a financial services & technology focused private equity firm, on its acquisition of Global Payment’s Gaming Services Division, a leading provider of on-site and digital payment processing services to companies in the gaming industry, for $415mm
Clinigen Ltd’s Proleukin
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma